PDCD1 and non-small cell lung carcinoma: Immunotherapeutics such as immune checkpoint inhibitors, including monoclonal antibodies against programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved in recent years to treat NSCLC.